Tag Archives: IPO

Innovation Act Stalls in the House

Representative Goodlatte’s Innovation Act (H.R. 9) has been shelved for now, and will not receive a floor vote until September at the earlier. There is significant conflict between measures intended to deter patent trolls and the ability of non-profit institutional … Continue reading

Posted in Patent Reform Legislation | Tagged , , , , , , | 1 Comment

Ignorance is Bliss – for Teva

I did not pay much attention to the fairly recent panel decision in Bristol-Myers Squibb Co. v. Teva Pharma. USA, 757 F.3d 967 (Fed. Cir. 2014). It seemed like a fairly routine panel affirmance of the district court’s finding that … Continue reading

Posted in Obviousness | Tagged , , , , , , , , , , , | 1 Comment

Common Citation Document Launched By Trilateral Patent Offices

This posting came with a set of presentation slides which you can find at the end of the post. The Industry Trilateral (of which IPO is a member) initially proposed a Common Citation Document (CCD).  In response, the Trilateral have … Continue reading

Posted in Int'l Practice and Policy | Tagged , , , , , , , | Leave a comment

Siemens v. Saint-Gobain – What’s Sauce For The Goose May Leave The Gander Unscathed

Contributed by Jim Nelson, J.D., Ph.D. of Schwegman Lundberg & Woessner, P.A. The Siemens Medical Solutions USA, Inc. v. Saint-Gobain Ceramics & Plastics, Inc., (a copy is available at the end of this post) case presents a fundamental issue and … Continue reading

Posted in Federal Court | Tagged , , , , , , , , , , , , , , | Leave a comment